Joan Shaw
Hoofd Techniek/Wetenschap/O&O bij BELLUS HEALTH
Actieve functies van Joan Shaw
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BELLUS HEALTH | Hoofd Techniek/Wetenschap/O&O | 01-03-2020 | - |
Loopbaan van Joan Shaw
Eerdere bekende functies van Joan Shaw
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ATHERONOVA INC. | Hoofd Techniek/Wetenschap/O&O | 08-01-2013 | - |
Opleiding van Joan Shaw
| University of Delaware | Undergraduate Degree |
| West Chester University of Pennsylvania | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| Canada | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
AtheroNova, Inc.
 AtheroNova, Inc. Pharmaceuticals: MajorHealth Technology AtheroNova, Inc. operates as biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. The company was founded by Giorgio Zadini and Filiberto Zadini in 1997 and is headquartered in Irvine, CA. | Health Technology |
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
